ASIT biotech’s lead product is gp-ASIT+TM for grass pollen rhinitis is currently in Phase III development. Preclinical development of hdm-ASIT+TM (for house dust mite rhinitis) and pnt-ASIT+TM (for peanut allergy) should be available in H1 2020. Other ASIT+TM product candidates are currently in early discovery phase.
The preclinical, clinical and production process of gp-ASIT+TM for the treatment of allergic rhinitis can be fully leveraged for the development of allergen fragments from other allergens such as house dust mite, ragweed and food allergens like peanut and eggwhite. The flexibility of the platform allows for adaption of the process to particular characteristics of a specific allergen.